Dash Bio, based in Newton, MA, raised $6.5M in Seed funding. The round was led by Freestyle Capital, with participation from Swift Ventures, LifeX Ventures, and other private investors.

Life X Ventures

Swift Ventures

Freestyle Capital

Dash Bio is revolutionizing clinical bioanalysis to expedite drug development. By leveraging AI and robotics, we deliver higher-quality assays with turnaround times up to 10x faster than the industry average for clinical trials and GLP studies.


Dash Bio raised $6.5M in Seed funding led by Freestyle Capital to expand operations and development efforts in tech-enabled drug development services.

Investors

Description

Company Information

Related People

Funding Insights

Dash Bio raised $6.5M in Seed funding led by Freestyle Capital to expand operations and development efforts in tech-enabled drug development services.

Investors

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information